Newbury Pharmaceuticals AB (publ)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NEWBRY.ST research report →
Companywww.newburypharma.com
Newbury Pharmaceuticals AB (publ) operates as hybrid pharmaceutical company in Sweden, and Scandinavian market. It offers oncology, rare diseases, neurology, and other treatment products. The company was incorporated in 2020 and is based in Lund, Sweden.
- CEO
- Karl Alexius Tiger Karlsson
- IPO
- 2022
- Employees
- 6
- HQ
- Lund, SE
Price Chart
Valuation
- Market Cap
- $36.29M
- P/E
- -1.69
- P/S
- 30.19
- P/B
- 0.95
- EV/EBITDA
- -1.13
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -345.67%
- Op Margin
- -2096.34%
- Net Margin
- -2097.00%
- ROE
- -55.06%
- ROIC
- -46.71%
Growth & Income
- Revenue
- $0 · -100.00%
- Net Income
- $-20,607,000 · -33.77%
- EPS
- $-0.83 · -15.28%
- Op Income
- $-20,607,000
- FCF YoY
- 45.23%
Performance & Tape
- 52W High
- $3.04
- 52W Low
- $0.76
- 50D MA
- $1.20
- 200D MA
- $1.63
- Beta
- 1.22
- Avg Volume
- 58.67K
Get TickerSpark's AI analysis on NEWBRY.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our NEWBRY.ST Coverage
We haven't published any research on NEWBRY.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate NEWBRY.ST Report →